297 related articles for article (PubMed ID: 36988504)
1. Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic.
Al-Mansour F; Alraddadi A; He B; Saleh A; Poblocka M; Alzahrani W; Cowley S; Macip S
Aging (Albany NY); 2023 Mar; 15(7):2373-2394. PubMed ID: 36988504
[TBL] [Abstract][Full Text] [Related]
2. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
[TBL] [Abstract][Full Text] [Related]
4. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
[TBL] [Abstract][Full Text] [Related]
5. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
[TBL] [Abstract][Full Text] [Related]
6. Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
Okabe S; Tanaka Y; Moriyama M; Gotoh A
Cancer Chemother Pharmacol; 2020 Feb; 85(2):401-412. PubMed ID: 31901955
[TBL] [Abstract][Full Text] [Related]
7. From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs.
L'Hôte V; Mann C; Thuret JY
Open Biol; 2022 Sep; 12(9):220171. PubMed ID: 36128715
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence.
Fan Z; Tong Y; Yang Z; Wang S; Huang T; Yang D; Ni Q; Zhang M; Li D; Yang M; Fan X
Exp Gerontol; 2024 Feb; 186():112359. PubMed ID: 38184267
[TBL] [Abstract][Full Text] [Related]
9. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
[TBL] [Abstract][Full Text] [Related]
10. The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
Ishikawa C; Mori N
Eur J Haematol; 2020 Dec; 105(6):763-772. PubMed ID: 32780889
[TBL] [Abstract][Full Text] [Related]
11. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
[TBL] [Abstract][Full Text] [Related]
12. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells.
Le HH; Cinaroglu SS; Manalo EC; Ors A; Gomes MM; Duan Sahbaz B; Bonic K; Origel Marmolejo CA; Quentel A; Plaut JS; Kawashima TE; Ozdemir ES; Malhotra SV; Ahiska Y; Sezerman U; Bayram Akcapinar G; Saldivar JC; Timucin E; Fischer JM
EBioMedicine; 2021 Nov; 73():103646. PubMed ID: 34689087
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
Mondello P; Derenzini E; Asgari Z; Philip J; Brea EJ; Seshan V; Hendrickson RC; de Stanchina E; Scheinberg DA; Younes A
Oncotarget; 2017 Feb; 8(8):14017-14028. PubMed ID: 28147336
[TBL] [Abstract][Full Text] [Related]
14. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms.
Wang Y; Wen J; Sun X; Sun Y; Liu Y; Cheng X; Wu W; Liu Q; Ren F
Cancer Chemother Pharmacol; 2024 Apr; 93(4):295-306. PubMed ID: 37938423
[TBL] [Abstract][Full Text] [Related]
15. Discovering small-molecule senolytics with deep neural networks.
Wong F; Omori S; Donghia NM; Zheng EJ; Collins JJ
Nat Aging; 2023 Jun; 3(6):734-750. PubMed ID: 37142829
[TBL] [Abstract][Full Text] [Related]
16. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
17. CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance.
To KKW; Fu LW
Invest New Drugs; 2018 Feb; 36(1):10-19. PubMed ID: 28819699
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of class 1-PI3K-alpha and delta isoforms causes senolysis by inducing p21
Neuwahl J; Neumann CA; Fitz AC; Biermann AD; Magel M; Friedrich A; Sellin L; Stork B; Piekorz RP; Proksch P; Budach W; Jänicke RU; Sohn D
Cell Death Dis; 2024 May; 15(5):373. PubMed ID: 38811535
[TBL] [Abstract][Full Text] [Related]
19. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics.
Zhang L; Pitcher LE; Prahalad V; Niedernhofer LJ; Robbins PD
FEBS J; 2023 Mar; 290(5):1362-1383. PubMed ID: 35015337
[TBL] [Abstract][Full Text] [Related]
20. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
